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RESEARCH ARTICLE
Shed syndecan-2 inhibits angiogenesis
Giulia De Rossi1, Alun R. Evans1, Emma Kay1, Abigail Woodfin1, Tristan R. McKay2, Sussan Nourshargh1 and
James R. Whiteford1,*
ABSTRACT
Angiogenesis is essential for the development of a normal
vasculature, tissue repair and reproduction, and also has roles in
the progression of diseases such as cancer and rheumatoid
arthritis. The heparan sulphate proteoglycan syndecan-2 is
expressed on mesenchymal cells in the vasculature and, like the
other members of its family, can be shed from the cell surface
resulting in the release of its extracellular core protein. The purpose
of this study was to establish whether shed syndecan-2 affects
angiogenesis. We demonstrate that shed syndecan-2 regulates
angiogenesis by inhibiting endothelial cell migration in human and
rodent models and, as a result, reduces tumour growth.
Furthermore, our findings show that these effects are mediated by
the protein tyrosine phosphatase receptor CD148 (also known as
PTPRJ) and this interaction corresponds with a decrease in active
b1 integrin. Collectively, these data demonstrate an unexplored
pathway for the regulation of new blood vessel formation and
identify syndecan-2 as a therapeutic target in pathologies
characterised by angiogenesis.
KEY WORDS: Angiogenesis, Inflammation, Syndecan, Integrin,
Endothelial cell migration
INTRODUCTION
Angiogenesis is a feature of development, wound healing,
tumorigenesis and chronic inflammatory conditions, such as
rheumatoid arthritis and atherosclerosis (Carmeliet, 2003; Mapp
and Walsh, 2012). The process requires the transition of
endothelial cells from a quiescent state to a migratory and
proliferative phenotype, and is stimulated and controlled by
growth factors, most notably vascular endothelial growth factor
(VEGF) (Sakurai and Kudo, 2011). Endothelial cell migration is a
crucial component of angiogenesis and integrins are the major
drivers of this response (Ramjaun and Hodivala-Dilke, 2009).
Integrins exist in various activation states on the cell surface and
this modulates the migratory and adhesive characteristics of cells
through interactions with the extracellular matrix (ECM). Other
cell surface receptors also interact with ECM ligands leading to
signalling cascades that can alter the activation state of integrins
(Streuli and Akhtar, 2009). The four-member syndecan family of
heparan sulphate proteoglycans (HSPGs) are an example of such
molecules.
The syndecans are a family of transmembrane receptors with
roles in cell adhesion, migration and growth factor signalling. In
common with the other family members, syndecan-2 has a short
cytoplasmic domain, a single-pass transmembrane domain and a
larger extracellular domain, which is modified toward the N-
terminus with heparan sulphate (HS) side chains and can be shed
from the cell surface. Many cell types shed syndecan ectodomains
through the action of matrix metalloproteinases (MMPs) in
response to a variety of stimuli including inflammatory
mediators, but the biological implications of this response are
not fully understood (Manon-Jensen et al., 2010). In the present
study, the possibility that shed syndecan-2 might be a regulator of
angiogenesis was investigated.
There is a considerable body of work to suggest that syndecan
extracellular core proteins have domains that influence cell
behaviour. For example, cell adhesion regulatory domains have
been identified in all four syndecan family members (De Rossi
and Whiteford, 2013a; De Rossi and Whiteford, 2013b; McFall
and Rapraeger, 1997; McFall and Rapraeger, 1998; Whiteford
et al., 2007; Whiteford and Couchman, 2006). How and when
these regulatory sequences function and their relevance to
biological processes has yet to be determined. Previously, we
have shown that the syndecan-2 extracellular core protein (S2ED)
can support fibroblast attachment and spreading (Whiteford et al.,
2007). Here, we show that S2ED shed from cells acts to inhibit
angiogenesis in both rodent and human models through a
paracrine interaction with the protein tyrosine phosphatase
receptor CD148. This interaction leads to a de-activation of b1
integrins resulting in a reduction in endothelial cell migration.
RESULTS
Constitutively released syndecan-2 ectodomain inhibits
angiogenesis in a xenograft tumour model
To investigate the potential effects of shed syndecan-2 on
angiogenesis we established a mammalian expression system in
which a constitutively released form of the molecule (lacking
both transmembrane and cytoplasmic domains, M1–F141, eS2ED)
was expressed in HEK293t cells (Fig. 1A). The HA epitope was
also incorporated into eS2ED between D27 and K28 enabling us to
readily detect eS2ED in conditioned media as compared to
controls transfected with empty vector (Fig. 1B; supplementary
material Fig. S1). Using these cell lines, we investigated the anti-
angiogenic properties of shed syndecan-2 in a xenograft tumour
model. Specifically, SCID-SHO mice were injected with empty
vector cells or cells that constitutively released syndecan-2
(eS2ED) and tumour sizes were quantified at 21 days. Mice
injected with control (empty vector) cells developed vascularised
tumours that were significantly larger both in terms of diameter
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Fig. 1. Constitutively released syndecan-2 extracellular core protein from HEK293t cells inhibits angiogenesis in a xenograft tumour model.
(A) Schematic diagram of syndecan-2 lacking both cytoplasmic and transmembrane domains (eS2ED), which is constitutively released from HEK293t cells.
(B) Dot blot of conditioned media from cells transfected with either empty vector (EV) or eS2ED constructs. Dot blots were probed with the anti-HA antibody,
and a strong signal is obtained from cells transfected with eS2ED. (C) Constitutively released syndecan-2 inhibits tumour growth. Micrograph of tumours
from SCID-SHO mice injected with either empty vector cells or eS2ED cells. Scale bar: 1 cm. (D) Tumours derived from eS2ED cells have smaller diameter.
Error bars represent the s.e.m. **P,0.01 (n55 tumours per condition, Student’s t-test. (E) Empty vector cells and S2ED cells have the same growth
kinetics over 96 h in culture. (F) Immunofluorescence staining of tumour sections derived from empty vector cells and eS2ED-transfected cells for the endothelial
cell marker CD31 (red; tumour cells are GFP positive). Considerably more CD31-positive structures are evident in tumours derived from cells transfected
with empty vector as compared the tumours in which syndecan-2 is constitutively released. Scale bar: 200 mm. (G) Quantification of the area of micrographs
positive for CD31 was performed and expressed as a percentage of the GFP-positive tumour cells. Data are the mean from three separate images from sections
of three tumours per group. Error bars represent the s.e.m. ****P,0.0001 (unpaired Student’s t-test).
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and weight as compared to tumours generated in mice injected
with the eS2ED cells (Fig. 1C,D; supplementary material Fig.
S2). We compared the growth kinetics in culture between empty
vector cells and eS2ED-transfected cell lines and found no
differences, indicating that cell proliferation defects were not the
reason tumours derived from eS2ED cells failed to develop
(Fig. 1E). Immunofluorescence staining of tumour sections for
the endothelial cell marker CD31 (also known as PECAM1)
revealed that tumours derived from empty vector control cells
contained CD31-positive structures consistent with blood vessels.
CD31-positive cells were greatly reduced in tumour sections
derived from cells constitutively releasing syndecan-2
(Fig. 1F,G). These findings suggest that constitutive release of
the syndecan-2 ectodomain in this model is inhibitory to
angiogenesis.
The shed syndecan-2 ectodomain inhibits angiogenesis
We next explored the possibility that the syndecan-2 ectodomain
cleaved from the cell surface in response to a known inducer of
syndecan shedding, the pro-inflammatory mediator TNFa, could
regulate angiogenesis (Pruessmeyer et al., 2010). HEK293t cells
transfected with full-length HA-tagged syndecan-2 cDNA (eFLS2,
Fig. 2A) expressed an abundance of cell surface syndecan-2 as
demonstrated by flow cytometry, and the presence of HS chains
was confirmed by western blotting (supplementary material
Fig, S3B,C). These cells were stimulated with TNFa for 4 h and
the medium was analysed for the HA-tagged shed syndecan-2
ectodomain. TNFa was found to induce shedding of syndecan-2 in
a concentration-dependent manner (Fig. 2B). To investigate the
potential impact of the shed molecule on angiogenesis, we
performed anion exchange on conditioned media to isolate the
HSPGs from empty vector and eFLS2-transfected cells stimulated
with TNFa, and also on conditioned media from cells
constitutively releasing eS2ED. The resulting HSPG-enriched
samples were incorporated into collagen matrices into which rat
aortic rings were embedded. Rings grown in the presence of empty
vector eluates exhibited normal sprout formation. However, eluates
containing shed syndecan-2, either TNFa-induced (eFLS2) or
constitutively released (eS2ED), strongly inhibited angiogenic
sprout formation (Fig. 2C). These data suggest that the anti-
angiogenic properties of the syndecan-2 ectodomain are retained
when syndecan-2 is shed from the cell surface.
The anti-angiogenic properties of shed syndecan-2 reside in
the extracellular core protein of the molecule
In the following series of experiments, we further explored the
impact of the extracellular core protein moiety of shed syndecan-
2 on angiogenesis. For this purpose, we used a bacterial
expression system to produce a fusion protein consisting of the
extracellular core protein [of murine syndecan-2 (E19–F141) fused
at the N-terminus to GST (S2ED, Fig. 3A) (Whiteford et al.,
2007; Whiteford et al., 2011)]. The resulting protein is easily
purified using glutathione and is not modified with HS chains
because prokaryotes lack the requisite transferases (Whiteford
et al., 2007). We incorporated S2ED into Matrigel plugs injected
sub-dermally in the abdomen of C57BL/6 mice. After 5 days,
plugs containing GST alone contained both CD31+ endothelial
cells and blood, a possible indication of new blood vessel
formation (Fig. 3B,C). In contrast plugs containing S2ED showed
a notable reduction in angiogenesis as indicated by a reduced
number of CD31+ endothelial cells (Fig. 3B,C). In addition,
analysis of Matrigel plugs for haemoglobin content indicated less
blood, indicative of reduced vascular formation in plugs
incorporating S2ED as compared to those with GST alone
(Fig. 3B; supplementary material Fig. S4A).
Having demonstrated the regulatory effects of S2ED on
angiogenesis in vivo, we expanded these studies to both ex vivo
and in vitro models of angiogenesis. Rat aortic explants were
embedded into collagen I gels in which either GST (control) or
S2ED was incorporated in the presence of VEGF. Whereas S2ED
inhibited sprout formation in a concentration-dependent manner,
rings grown in the presence of GST were unaffected by this
treatment and sprouted to the same degree as untreated controls
(Fig. 3D). S2ED also inhibited VEGF-induced angiogenesis in a
model employing aortic rings from C57BL/6 mice (supplementary
material Fig. S4B). The effect of S2ED in vitro was tested on
Fig. 2. Shed syndecan-2 from HEK293t cells has anti-angiogenic properties. (A) Schematic diagram of full-length HA-tagged syndecan-2 (eFLS2), which
was expressed in HEK293t cells. (B) Syndecan-2 is shed from HEK293t cells after stimulation with TNFa in a dose-dependant manner. eFLS2 cells were
incubated for 4 h in serum-free media with the indicated concentration of TNFa, and conditioned media were assayed by dot blot using the anti-HA antibody. EV,
empty vector. (C) Shed syndecan-2 is anti-angiogenic. Empty vector cells and eFLS2 cells were treated with TNFa (200 ng/ml) for 4 h and the shed
proteoglycans were purified by anion exchange. Proteoglycans were also isolated from conditioned media from eS2ED transfected cells using the same
methodology. 10 mg of each protein preparation was incorporated into collagen I gels and then seeded with rat aortic rings as described in the Materials and
Methods. Sprouts from eight rings were counted and results are mean6s.e.m. ****P,0.0001 (one-way ANOVA comparing to empty vector controls using the
Tukey’s camparisons test).
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human umbilical vein endothelial cell (HUVEC) tube formation
when in 3D co-culture with human dermal fibroblasts using the
commercially available V2A vasculogenesis to angiogenesis kit.
After 2 weeks in culture under control conditions, tubule structures
were formed with branch points (Fig. 3E). This effect could be
augmented with the addition of VEGF and inhibited by the addition
of Suramin. The addition of GST to the culture medium had little
effect on either the length of tubules formed or the number of
branch points as compared to the control medium. In contrast, in
the presence of S2ED a significant reduction in tubule length and
branch points was noted (Fig. 3F,G). Taken together, these results
demonstrate that the syndecan-2 extracellular core protein has
Fig. 3. See next page for legend.
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anti-angiogenic properties in both rat, murine and human model
systems.
The anti-angiogenic properties of S2ED reside in the
syndecan-2 adhesion regulatory domain
Given that we have previously shown that fibroblast adhesion to
S2ED is regulated by the C-terminal 18-amino-acid domain
between P124 and F141 of murine syndecan-2 (Whiteford et al.,
2011), we hypothesised that this adhesion regulatory region of
syndecan-2 might also be responsible for the inhibition of
angiogenesis. This was initially investigated by performing rat
aortic ring assays with deletion mutants of S2ED (Fig. 4A). Full
length S2ED, S2EDDP124–F141 (lacking the adhesion regulatory
domain) or S2EDDL73–G123 (a truncated form containing only
the adhesion regulatory residues) were incorporated into collagen
matrices in which aortic ring sections were embedded
(Fig. 4A,B). Although angiogenic sprouts were observed in
both untreated and GST controls, sprout formation was severely
compromised when rings were embedded in matrices with S2ED
or S2EDDL73–G123 both of which contain the regulatory 18-
amino-acid motif (Fig. 4B). These data indicate that the anti-
angiogenic properties of S2ED are dependent on the adhesion
regulatory domain lying between P124 and F141 of murine
syndecan-2.
S2ED inhibits endothelial cell migration
As endothelial cell migration is a crucial component of
angiogenesis, the following series of experiments aimed to
investigate the effect of S2ED on this response. To establish
whether the anti-angiogenic effect of S2ED is due to the
inhibition of endothelial cell migration by residues contained
within the 18-amino-acid regulatory domain, we performed
migration assays on brain endothelial cells in the presence of
either S2ED or the truncated forms of this protein (S2EDDP124–
F141 and S2EDDL73–G123). As found with the full-length protein,
the truncated fusion protein containing only the adhesion
regulatory domain (S2EDDL73–G123), inhibited endothelial cell
migration (Fig. 4C,D). In contrast, the mutant protein lacking the
syndecan-2 adhesion regulatory domain did not affect cell
migration, with the wound closure being equivalent to that
noted with cells treated with GST alone. The inhibitory effect of
S2ED on endothelial cell migration was evident regardless of the
vascular bed from which the endothelial cells originated because
both skin and lung endothelial cells responded to S2ED and the
mutant proteins in a similar manner (supplementary material Fig.
S4C). Taken together, these data show that the effect of S2ED on
endothelial cell migration is regulated by the C-terminal 18-
amino-acid regulatory domain.
We also tested the effects of S2ED on endothelial cell invasion
into collagen I gels and observed that cell invasion was greatly
inhibited when S2ED was incorporated as compared to controls
(Fig. 4E). Of importance, neither protein impacted upon cell
proliferation (Fig. 3F). These data are in disagreement with the
findings of a previous report (Fears et al., 2006) in which it was
suggested that S2ED could promote endothelial cell invasion
and stimulate longer microtubules in networks formed when
endothelial cells are seeded on Matrigel. In trying to recapitulate
this work we observed that S2ED inhibited endothelial cell
invasion through Matrigel and had no measurable effect on
network formation when sEND cells were seeded on Matrigel
(supplementary material Fig. S4D,E). These results also show an
inhibitory effect on endothelial cell invasion by S2ED and this is
likely to be through inhibition of cell migration.
The inhibition of angiogenesis by S2ED is driven by CD148,
leading to changes in b1 integrin activation
In fibroblasts the protein tyrosine phosphatase receptor CD148
(also known as PTPRJ) interacts directly with the adhesion
regulatory domain of S2ED leading to b1-integrin-mediated cell
attachment and spreading (Whiteford et al., 2011). To determine
whether CD148 is a mediator for endothelial cell responses to
S2ED, we first confirmed that endothelial cells from brain, lung
and skin expressed CD148. Western blot analysis using an
antibody directed to the cytoplasmic domain of CD148 revealed
that all three cell lines expressed this receptor (Fig. 5A). We then
demonstrated that there was an interaction between CD148 and
the syndecan-2 ectodomain by performing a pulldown assay using
GST–S2ED beads as bait. No CD148 was evident in precipitates
in which GST- or GST–S2EDDP124–F141-coated beads were used
(Fig. 5B). S2ED and S2EDDL73–G123, which both contain the C-
terminal 18-amino-acid adhesion regulatory domain successfully
pulled down CD148 from endothelial cell lysates indicating that
the interaction point between CD148 and S2ED resides in this
region of the molecule.
We next performed rat aortic ring experiments using a purified
recombinant form of the CD148 extracellular domain comprising
the first five type III fibronectin repeats of the human form of this
molecule. This also proved inhibitory to angiogenesis to the same
degree as S2ED, and when used in conjunction with S2ED the
anti-angiogenic effect appeared enhanced (Fig. 5C).
The impact of S2ED on endothelial cell b1 integrin activation
was examined next. Endothelial cells treated with S2ED showed
reduced binding of the b1 integrin activation marker, the
monoclonal antibody (mAb) 9EG7, as demonstrated by
fluorescence activated cell sorting (FACS) (Fig. 6A). Using this
antibody for immunofluorescent staining of endothelial cells, a
substantial reduction in active b1 integrins was observed in cells
treated with S2ED (Fig. 6B,C). Interestingly this effect was most
pronounced at the leading edge of scratch wounds, where the
highest expression of active b1 integrins was noted in control and
GST-treated cells. We further tested the effect of S2ED on b1
Fig. 3. The syndecan-2 extracellular core protein inhibits angiogenesis.
(A) Schematic diagram of S2ED consisting of GST fused to the syndecan-2
ectodomain core protein. (B) Angiogenesis is inhibited by S2ED when
incorporated into Matrigel. C57BL/6 mice were given sub-dermal injections of
Matrigel supplemented with VEGF and FGF containing either 0.5 mM of
S2ED or GST. Excised sections of Matrigel plugs were immunostained for
CD31 (endothelial cells) and DRAQ5 (all cell nuclei) and analysed by
confocal microscopy, and the percentage of cells positive for CD31
calculated. Less endothelial cells migrate into Matrigel plugs containing
S2ED. Error bars represent the s.e.m. of four separate images. *P,0.05
(Mann–Whitney t-test). (C) Photographs of plugs after excision. (D) The anti-
angiogenic effects of S2ED are dose dependant. Rat aortic rings were
seeded in collagen I containing the indicated concentrations of GST or
S2ED and the angiogenic sprouts counted after 4 days. Data were obtained
from at least 10 rings from four separate rats per condition. *P,0.05,
**P,0.01 (one-way ANOVA comparing to untreated controls using the
Tukey’s comparisons test). (E) S2ED inhibits tubule formation in a HUVEC
co-culture system. Using the V2a kit, HUVECs and fibroblasts were co-
cultured in the presence of VEGF, Suramin, S2ED and GST. Micrographs,
showing fewer tubules, were obtained in the presence of S2ED and these
were shorter (F) and less branched (G; branch points denoted by arrows).
Scale bar: 500 mm. Error bars represent the s.e.m. of four separate images.
*P,0.05, **P,0.01, ****P,0.0001 (Mann–Whitney t-test).
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integrin activation in HUVECs. Stimulation of HUVECs with
Mn2+ lead to an increase in structures that bound the mAb
HUTS4 and this was unaffected by the addition of GST. Positive
staining was greatly reduced when cells were treated with S2ED
(Fig. 6D). Taken together, these results suggest that the anti-
migratory effects of S2ED on endothelial cells might be mediated
by CD148 signalling, an interaction that could lead to a reduction
in active b1 integrins on the surface of endothelial cells (Fig. 6).
DISCUSSION
The use of inhibitors for the suppression of pathological
angiogenesis is well established, although clinical evidence
Fig. 4. See next page for legend.
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suggests that there are a number of complications and side effects
(Duda et al., 2007). There is therefore a need for greater
understanding of the regulatory mechanisms that both promote
and inhibit new blood vessel formation in order to develop new
more effective therapeutic targets. We propose a previously
unreported role for syndecan-2, in that, in its shed form,
syndecan-2 can act to inhibit angiogenesis by slowing
endothelial cell migration, through an interaction with CD148
leading to changes in b1 integrin activation (Fig. 7). The
identification of the syndecan-2 adhesion regulatory domain as
a strong negative regulator of angiogenesis mean that both it and
its binding partner CD148 are potential novel therapeutic targets
in pathologies where angiogenesis is a feature, such as
atherosclerosis, arthritis and cancer.
Angiogenesis requires the action of numerous pro- and anti-
angiogenic factors that collectively provide the signals necessary
for the generation of new blood vessels. Here, we demonstrate
that one such factor is the extracellular core protein of syndecan-2
that, when shed from cells, can negatively regulate angiogenesis.
Syndecan shedding is a feature of many cell types and occurs in
response to stimuli such as inflammatory mediators and growth
factors (Manon-Jensen et al., 2010; Pruessmeyer et al., 2010).
Both MMP-7 and MMP-9 have been identified as having a role in
the shedding of syndecan-2 (Fears et al., 2006; Kwon et al.,
2014). As yet the cleavage sites for syndecan-2 shedding have not
been identified; however, the eukaryotic expression system
described here will provide an useful tool to address this
important question. Shedding studies on syndecan-4, the most
closely related member of this family to syndecan-2, suggest that
the entire ectodomain can be cleaved from the cell surface
(Manon-Jensen et al., 2013). The fact that shed syndecan-2
influences angiogenesis and that the regulatory region resides
between P124 and F141 of the ectodomain, close to the syndecan-2
transmembrane domain, suggests that, like syndecan-4, the entire
ectodomain is shed in response to inflammatory stimuli.
Fig. 4. The anti-angiogenic properties of S2ED are due to inhibition of
endothelial cell migration and are mediated by amino acids P124–F141.
(A) Diagram of the mutant proteins used in this study. Full-length syndecan-2
extracellular core protein S2ED comprising E19–F141, a truncated form of
S2ED lacking the adhesion regulatory domain, S2EDDP124–F141 (green),
and a mutant containing only the GAG attachment domain and the C-
terminal adhesion regulatory domain, S2EDDL73–G123. (B) The adhesion
regulatory domain of syndecan-2 inhibits angiogenic sprout formation. Rat
aortas were seeded in collagen I matrices containing 0.5 mM of GST, S2ED
or the mutant forms of S2ED. Sprouts from eight rings per condition were
counted and the mean calculated. Error bars represent the s.e.m.
***P,0.005, ****P,0.0001 (one-way ANOVA with Bonferroni multiple
comparison). (C,D) Scratch wound migration assays were performed in the
presence of 0.5 mM of the indicated fusion proteins on brain endothelial cells.
(D) Endothelial cell migration speed is reduced in the presence of S2ED
proteins containing the 18-amino-acid regulatory domain. Cell speed data
represents mean6s.e.m. measurements from at least 25 individual cells at
the leading edge per treatment. (E) S2ED inhibits endothelial cell invasion
into collagen I matrices. GST or S2ED (0.5 mM) were incorporated into
collagen I matrices in transwells. After 6 h, cells that had migrated were
counted and the data represents the mean6s.e.m. of triplicate assays.
*P,0.05 (by Student’s t-test). (F) Cell proliferation is unaffected by S2ED.
Confluent monolayers of sEND cells were grown in the presence of 0.5 mM of
the proteins indicated and mean proliferation measurements were calculated
from four wells per condition.
Fig. 5. S2ED interacts with CD148, resulting in the inhibition of angiogenesis. (A) bEND3.1, MLEC and sEND cells express CD148. Western blot of
lysates from the endothelial cell lines indicated were probed with antibodies against CD148 or b-tubulin. (B) CD148 interacts with S2ED. Cell lysates from
sEND cells were incubated with beads coated with GST, S2ED, S2EDDP124–F141 or S2EDDL73–G123. Precipitates were analysed by western blotting for the
presence of CD148. CD148 was only pulled down by forms of S2ED which contain the C-terminal 18-amino-acid adhesion regulatory domain. The blot is
representative of four experiments. (C) Soluble CD148 inhibits angiogenesis. Rat aortic rings were embedded in collagen I with either 0.5 mM S2ED or 0.5 mM of
soluble (sol) CD148, or both proteins in combination, in the presence of VEGF. Both S2ED and soluble CD148 inhibited sprout formation to the same degree,
and also inhibited angiogenesis when used in combination. Data are the mean from aortas from five animals and errors bars reflect the s.e.m. *P,0.05,
***P,0.001 (Student’s t-test comparing values to the untreated VEGF control).
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Regulatory sequences in the syndecan-1 and, more recently,
the syndecan-3 ectodomain have been identified and these have
also been shown to be anti-angiogenic (Beauvais et al., 2004;
Beauvais et al., 2009; De Rossi and Whiteford, 2013b). However,
the evidence presented here suggests that shed syndecan-2 acts on
endothelial cells through a mechanism distinct to that associated
with syndecan-1 and -3. Syndecan-1 is thought to interact directly
with aV integrins, leading to changes in cell adhesion
Fig. 6. See next page for legend.
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characteristics through an autocrine interaction with IGFR-1
(Beauvais and Rapraeger, 2010; Rapraeger et al., 2013). We
propose that shed syndecan-2 acts in a paracrine fashion given
that the adhesion regulatory domain of syndecan-2 is situated
very close to the transmembrane domain of the full-length
molecule. The presence of glycosaminoglycan (GAG) chains and
the respective sizes of the receptors involved make it hard to
envisage how an autocrine interaction between these CD148 and
syndecan-2 could occur. Whether regulation of angiogenesis is a
common feature of all four syndecan ectodomains is an attractive
possibility that requires further investigation.
We showed that the anti-angiogenic effect of the syndecan-2
ectodomain is observed in both rodent and human models of
angiogenesis, and involves the interaction with the protein
tyrosine phosphatase receptor CD148 on the surface of
endothelial cells, which corresponds with the inactivation of b1
integrins. b1 integrins are intimately associated with angiogenesis
and endothelial cell migration (Mettouchi and Meneguzzi, 2006).
Our previous work using fibroblasts has shown that engagement
of CD148 with S2ED leads to the de-phosphorylation of the
p85 subunit of phosphoinositide 3-kinase (PI3K) and that there
is a requirement for Src kinase in this process. Furthermore,
clustering of CD148 with cognate antibodies leads to b1-integrin-
mediated fibroblast adhesion responses (Whiteford et al., 2011).
It is likely that this same signalling pathway is functional in
endothelial cells, and that these signalling molecules are involved
in the reduction in active b1 integrins on the surface of
endothelial cells in response to S2ED. CD148 is known to be
involved in the inhibition of cell migration in leukocytes, notably
neutrophils and macrophages (de la Fuente-Garcı´a et al., 1998;
Zhu et al., 2008; Zhu et al., 2011), and, here for the first time we
show it also has a role in regulating endothelial cell migration.
Another ECM component, thrombospondin, has also been
identified as a ligand for CD148, and this molecule is also
known to bind HS, and is an inhibitor of angiogenesis (Takahashi
et al., 2012). It is tempting to speculate that these three molecules
are involved in some form of cell migration regulatory complex
within the ECM, particularly as endothelial cell responses to
thrombospondin-1 have been shown to involve b1 integrin.
Syndecan-2 and CD148 are molecules intimately associated
with the vasculature. Syndecan-2 is expressed on fibroblasts,
leukocytes and endothelial cells, and studies in zebrafish have
revealed that syndecan-2 is essential for branching angiogenesis
(Chen et al., 2004). Here, we show that CD148 is present on
endothelial cells from three distinct vascular beds (brain, skin and
lung). CD148-null mice are viable and show no gross defects;
however, a knock-in mouse expressing a catalytically dead form
of CD148 in which the cytoplasmic domain is replaced by eGFP
dies early in development due to a failure in vascularisation
(Takahashi et al., 2003; Trapasso et al., 2006). Quite why the
cytoplasmically mutated form of CD148 elicits such a strong
Fig. 6. Active b1 integrin is reduced on endothelial cells in the presence
of S2ED. (A) Active b1 integrin on sEND cells positive for total b1 integrin is
reduced in S2ED-treated cells as measured by FACS. The number of
endothelial cells with active b1 integrin (as recognised by the monoclonal
antibody 9eG7) was expressed as a percentage of total b1-integrin-
expressing cells and plotted on the bar chart (right) left and dot blots
corresponding to each treatment (left). (B) Micrographs of scratch wounds
showing that active b1 integrin is reduced in endothelial cells treated with
S2ED. Active b1 integrin is shown in green and DAPI in blue. Scratch
wounds were performed on confluent monolayers and were incubated in the
presence of the indicated proteins (0.5 mM) for 30 min prior to staining.
Graphs represent the fluorescent intensity profile of active b1 integrin across
the scratch wounds. The data was obtained from the section represented by
the lines indicated on the micrographs. Scale bar: 200 mm. (C) Higher
magnification micrographs (636) of endothelial cells treated as indicated.
Scale bar: 10 mm. Cells were stained for F-actin (red), DRAQ5 (blue) and
active b1 integrin (green). (D) S2ED causes a reduction in active b1 integrin
on HUVECs. HUVECs were treated with 1 mM MnCl2 in the presence of
0.5 mM GST or S2ED. Untreated cells or cells treated with GST showed an
increase in structures recognised by the monoclonal antibody HUTS4
(green). This was not the case with cells treated with S2ED. Inlays show
DAPI staining (blue) and merged images. Scale bar: 20 mm.
Fig. 7. Engagement of CD148 by shed
syndecan-2 corresponds with a reduction in
active b1 integrin in endothelial cells leading
to inhibition of cell migration and
less angiogenesis.
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phenotype is not clear. Our study suggests that engagement of
CD148 by its ligands results in an ablation of the angiogenic
process and this is supported by the fact that antibodies targeting
CD148 have anti-angiogenic affects (Takahashi et al., 2006). We
hypothesize that this CD148-driven response to S2ED represents a
signal whereby new blood vessel formation is halted, for example
at the site of tissue injury. In as much as promoting new blood
vessel formation is an important feature of wound healing, the
cessation of this process also represents an important step.
Syndecan-null animals also breed normally, are fertile and have
no gross abnormalities and it is only under challenge or insult that
these animals exhibit phenotypes (Ishiguro et al., 2002). It is
conceivable that the CD148-null mouse would exhibit similar
responses. An intriguing question would be how this mouse would
respond to wounding or models where excessive angiogenesis
occurs, such as in retinal angiogenesis or tumour models. This
work presents an unreported pathway for the inhibition of
angiogenesis and presents an alternative therapeutic target for
anti-angiogenic therapy to those currently on the market.
MATERIALS AND METHODS
Fusion proteins and antibodies
GST, S2ED, S2EDDP124–F141, S2EDDL73–G123 and soluble CD148 were
purified as described previously (Whiteford et al., 2011). Antibodies used
were anti-CD148 (R and D Systems), anti-CD29 clone 9EG7 (BD
Pharmingen), anti-mouse CD29 clone HMb1-1 (Biolegend), anti-CD29
clone HUTS4 (Millipore), Anti-HA (clone HA.11, Covance), anti-
syndecan-2 (AF6585, R and D systems) and anti b-tubulin (clone
TUB2.1, Sigma) antibodies, and Alexa-Fluor-488-conjugated anti-mouse
CD31 antibody (Clone MEC 13.3, Biolegend). Alexa-Fluor-568-
conjugated phalloidin was from Life Technologies.
Cell culture
All cells used in this study were grown at 37 C˚ under 10% CO2 in
Dulbecco’s modified Eagle’s medium (DMEM; PAA), supplemented
with 10% FBS, 2 mM L-glutamine, 1% non-essential amino acids, 1 mM
sodium pyruvate and 5 mM b-mercaptoethanol (all Invitrogen). Primary
murine lung endothelial cells were isolated and maintained as described
previously (Reynolds et al., 2002). HUVECs (HPA laboratories) were
grown and maintained in Endothelial Growth Medium (HPA
laboratories) and maintained as above.
Generation of syndecan-2-expressing cell lines
Gene synthesis of the complete murine syndecan-2 cDNA and the cDNA
encoding only the syndecan-2 ectodomain coding sequence was
performed by GeneArt (Invitrogen). Both full-length and truncated
syndecan-2 cDNAs were mutated such that the HA epitope was inserted
between D27 and K28 (supplementary material Fig. S1). BamHI sites were
also incorporated at the 59 and 39 end of the two synthetic genes. The
cDNAs were cloned into the BamHI site of the lentiviral vector pLNT-
SFFV-MCS-EGFP (available from T.R.M.). Lentiviruses were produced
in HEK293t cells and packaged into a VSVG coat using conventional
procedures. HEK293t cells were transfected using the supernatant
transfer method. Cells expressing high levels of eGFP were sorted by
flow cytometry and these were cultured in DMEM as described.
Tumour xenograft model
Six-week-old SCID SHO mice (Charles River) were subcutaneously
injected in the left flank with 36106 HEK293t cells stably transfected
with either empty vector or eS2ED in 100 ml PBS. Mice were left for 21
days prior to being killed by cervical dislocation. All experiments were
performed under the UK legislation for the protection of animals in
accordance with UK Home Office regulations. Tumours were dissected
and photographed and tumour mass and diameter was measured.
Tumours were then snap-frozen in liquid nitrogen prior to embedding
in OCT and sectioning (20 mm sections). Sections were fixed using
ice-cold methanol and immunostained with anti-CD31 antibodies
conjugated to Alexa Fluor 564 and imaged using a PASCAL laser-
scanning confocal microscope (Carl Zeiss) with a 106 objective.
Matrigel plug assay
Male 6-week-old C57BL/6 mice were given subdermal abdominal
injections consisting of 600 ml of Matrigel (BD Biosciences) mixed with
100 ml of PBS containing 100 ng/ml VEGF, 100 ng/ml FGF and 20 U/ml
of heparin and 0.5 mM of either GST or S2ED (following the method
described in Passaniti et al., 1992). Mice were killed after three days and
the plugs excised, photographed and incubated overnight in PBS.
Haemoglobin was quantified using Drabkin’s reagent (Sigma) as
described by the manufacturer. All experiments were performed under
the UK legislation for the protection of animals, and at the end of all in
vivo procedures involving anaesthesia, animals were humanely killed by
cervical dislocation in accordance with UK Home Office regulations.
Excised plugs were frozen in liquid nitrogen and subsequently embedded
in ice cold OCT, 15-mm sections were made using a cryostat at 220 C˚.
Following fixation with 4% paraformaldehyde (PFA) for 5 min and
blocking with 10% normal goat serum for 15 min, sections were stained
for nuclei (DRAQ5) and the endothelial cell marker CD31 overnight.
Images were captured using a PASCAL laser-scanning confocal
microscope (Carl Zeiss, 106objective). Quantification was performed
using the IMARIS software and Photoshop (Adobe), endothelial cells
were identified by co-localization of nuclei with CD31 staining.
Aortic ring assay
Thoracic aortas dissected from cervically dislocated 180–200 g male
wistar rats (Harlan laboratories) or 6-week-old C57BL/6 mice (Charles
River), and were sliced into 0.5-mm sections and incubated overnight in
serum-free OptiMEM (Invitrogen) at 37 C˚. Aortic rings were embedded
in type I collagen (1 mg/ml) in E4 medium (Invitrogen) containing GST,
syndecan-2 mutant proteins or peritoneal exudates in 48-well plates.
Wells were supplemented with OptiMEM with 1% FBS and 10 ng/ml
VEGF (R and D systems, 30 ng/ml for murine rings) and incubated at
37 C˚ under 10% CO2. Angiogenic sprouts from rat and mouse aortas
were counted after 4 days and 8 days respectively (method based on that
of Nicosia and Ottinetti, 1990 and modified in De Rossi et al., 2013).
In vitro tubule formation assays
HUVECs and human dermal fibroblasts were co-cultured using the Cell
Works V2a kit (Caltag Media Systems as described by the manufacturer).
Medium containing control compounds, GST or S2ED was changed
every second day and at day 14 endothelial cells were stained for CD31
to assess the tube formation. Imaging was performed using an Olympus
IX81 inverted microscope (106objective); tube length and branch points
were quantified using Photoshop (Adobe). A branch point was defined as
the point at which two or more tubules met, and the tubule length as the
length of tubules between branch points. In a second type of microtubule
assay, sEND cells (56104) were seeded into 24-well plates coated with
150 ml of Matrigel (BD sciences) in the presence of either GST or S2ED.
Using the Cell-IQ controlled environmental chamber (CM technologies)
plates were incubated at 37 C˚ under 10% CO2 and images were captured
every 15 min for 16 h.
Scratch wound migration assays
Scratch wound migration assays were performed on confluent
monolayers of endothelial cells. Wounds were made using a pipette
tip, and fusion proteins were added to the medium and images were
captured every 30 min for 12 h by time lapse microscopy using an
Olympus IX81 microscope. Percentage wound closure was calculated
and individual cells were tracked using Image J.
Invasion assay
Invasion assays through collagen and Matrigel matrices were performed
in 24-well plates with transwell inserts [Millipore; 8-mm pore size,
polyester (PET) membrane]. Membranes were coated with 10 ml of a
collagen type I mixture (Millipore; 1 mg/ml in E4 medium) containing
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0.5 mM GST or S2ED. sEND cells were seeded on the gel in a
homogenous single cell suspension of 5,000 cells/insert in 200 ml of
DMEM plus 10% FBS; 1 ml of the same medium was added to the
bottom well. Invasion was measured after 6 h after which time gels were
removed with a cotton swap, the filter washed in PBS and stained with
calcein (Invitrogen) and the number of cells attached to the filter counted.
Proliferation
Cell proliferation was measured using the CellTiter 96 AQueous Cell
proliferation assay kit as described by the manufacturer (Promega).
CD148 pulldown and western blotting
Confluent bEND3.1 cells were lysed in 1% Triton X-100 in Tris-buffered
saline (TBS) containing HALT protease and phosphatase inhibitors (Pierce).
GST and S2ED were bound to glutathione–Sepharose beads (GE Healthcare)
and were added to cell lysates and incubated for 1 h. Beads were isolated by
centrifugation and washed twice in TBS, prior to incubation in Laemmli
buffer and analysis by western blotting using standard procedures.
Dot blotting
Samples were diluted in blotting buffer (0.15 M NaCl buffered to pH 4.5
with 50 mM sodium acetate, with 0.1% Triton X-100) and applied under
vacuum to cationic nylon membranes (GE Healthcare; Amersham
HybondTM-N+). Membranes were washed three times with blotting
buffer, blocked for 1 h in blocking buffer (3% milk, 0.5% BSA, 0.15 M
NaCl in 10 mM Tris-HCl pH 7.4) and incubated overnight with primary
antibody in blocking buffer plus 0.3% Tween-20. After washing, blots
were incubated for 2 h with the appropriate horseradish peroxidase
(HRP)-conjugated secondary antibody and signals were detected by
chemi-luminescence using conventional procedures. Quantification of
the signal intensity was performed using ImageJ software.
FACS and immunofluorescence staining for active integrin
Confluent bEND3.1 cells were trypsinised and the trypsin inactivated
with BSA. Cells were re-suspended in Hank’s buffer (without Ca2+ and
Mg2+) containing the treatments described (0.5 mM GST or S2ED) and
incubated for 30 min at 37 C˚. Cells were then fixed in 2% PFA prior to
FACS analysis for both total and active b1 integrin and the percentage of
cells expressing active b1 calculated. For immunofluorescence staining
of active b1 integrin, confluent monolayers of sEND cells were grown on
microscope slides and scratch wounds were made and either 0.5 mM GST
or S2ED was added. After 30 min, cells were fixed with 4% PFA (Sigma)
and permeabilised in 0.1% Triton X-100 (Sigma) in PBS. Samples were
incubated with active b1-integrin-specific antibody 9EG7 in 1% normal
goat serum in PBS overnight at 4 C˚. Slides were washed in PBS and
incubated in anti-rabbit-IgG antibody conjugated to Alexa Fluor 488
(Molecular Probes) and DAPI, and images were captured on an Olympus
IX81 inverted microscope. Fluorescent intensity profiles from the
resulting images were calculated using ImageJ. For higher resolution
images, cells were imaged using a PASCAL laser-scanning confocal
microscope (Carl Zeiss) with a 636 objective and the resulting stacks
were processed using IMARIS software. HUVECs were seeded on
coverslips coated with fibronectin (10 mg/ml) and collagen I (30 mg/m) in
0.1% gelatin. Once ,60% confluent, cells were washed with serum-free
OptiMEM then treated either with or without 1 mM MnCl2 in the
presence of either 0.5 mM GST or S2ED for 30 min. Cells were then
fixed in 2% PFA and stained using a monoclonal active b1-integrin-
specific antibody (clone HUTS4, at 1:300). After washing, cells were
stained with an anti-mouse-IgG antibody conjugated to Alexa Fluor 594
(Molecular Probes). Cells were analysed by confocal microscopy as
described above.
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